S&P 500   3,136.90 (-0.29%)
DOW   27,919.65 (-0.34%)
QQQ   204.14 (-0.42%)
AAPL   267.03 (-1.36%)
FB   201.14 (+0.04%)
MSFT   151.35 (-0.26%)
GOOGL   1,343.74 (+0.32%)
AMZN   1,750.02 (-0.09%)
CGC   21.35 (+14.48%)
NVDA   212.26 (+0.04%)
MU   46.53 (-2.94%)
BABA   199.02 (-1.42%)
GE   11.03 (-0.63%)
TSLA   340.23 (+1.29%)
T   38.04 (-0.44%)
AMD   38.96 (-1.69%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
NFLX   302.93 (-1.44%)
BAC   33.56 (-0.33%)
S&P 500   3,136.90 (-0.29%)
DOW   27,919.65 (-0.34%)
QQQ   204.14 (-0.42%)
AAPL   267.03 (-1.36%)
FB   201.14 (+0.04%)
MSFT   151.35 (-0.26%)
GOOGL   1,343.74 (+0.32%)
AMZN   1,750.02 (-0.09%)
CGC   21.35 (+14.48%)
NVDA   212.26 (+0.04%)
MU   46.53 (-2.94%)
BABA   199.02 (-1.42%)
GE   11.03 (-0.63%)
TSLA   340.23 (+1.29%)
T   38.04 (-0.44%)
AMD   38.96 (-1.69%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
NFLX   302.93 (-1.44%)
BAC   33.56 (-0.33%)
S&P 500   3,136.90 (-0.29%)
DOW   27,919.65 (-0.34%)
QQQ   204.14 (-0.42%)
AAPL   267.03 (-1.36%)
FB   201.14 (+0.04%)
MSFT   151.35 (-0.26%)
GOOGL   1,343.74 (+0.32%)
AMZN   1,750.02 (-0.09%)
CGC   21.35 (+14.48%)
NVDA   212.26 (+0.04%)
MU   46.53 (-2.94%)
BABA   199.02 (-1.42%)
GE   11.03 (-0.63%)
TSLA   340.23 (+1.29%)
T   38.04 (-0.44%)
AMD   38.96 (-1.69%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
NFLX   302.93 (-1.44%)
BAC   33.56 (-0.33%)
S&P 500   3,136.90 (-0.29%)
DOW   27,919.65 (-0.34%)
QQQ   204.14 (-0.42%)
AAPL   267.03 (-1.36%)
FB   201.14 (+0.04%)
MSFT   151.35 (-0.26%)
GOOGL   1,343.74 (+0.32%)
AMZN   1,750.02 (-0.09%)
CGC   21.35 (+14.48%)
NVDA   212.26 (+0.04%)
MU   46.53 (-2.94%)
BABA   199.02 (-1.42%)
GE   11.03 (-0.63%)
TSLA   340.23 (+1.29%)
T   38.04 (-0.44%)
AMD   38.96 (-1.69%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
NFLX   302.93 (-1.44%)
BAC   33.56 (-0.33%)
Log in

NASDAQ:AKTX - Akari Therapeutics Stock Price, Forecast & News

$1.91
-0.07 (-3.54 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$1.88
Now: $1.91
$2.00
50-Day Range
$1.69
MA: $1.85
$2.06
52-Week Range
$1.56
Now: $1.91
$9.20
Volume154,288 shs
Average Volume540,783 shs
Market Capitalization$30.29 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.81
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKTX
CUSIPN/A
Phone646-350-0702

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.20 per share

Profitability

Net Income$-16,470,000.00

Miscellaneous

Employees17
Market Cap$30.29 million
Next Earnings Date4/28/2020 (Estimated)
OptionableNot Optionable

Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.


Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics PLC (NASDAQ:AKTX) issued its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. View Akari Therapeutics' Earnings History.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Akari Therapeutics.

What price target have analysts set for AKTX?

1 brokerages have issued twelve-month price targets for Akari Therapeutics' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Akari Therapeutics' share price to reach $7.00 in the next year. This suggests a possible upside of 268.4% from the stock's current price. View Analyst Price Targets for Akari Therapeutics.

What is the consensus analysts' recommendation for Akari Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akari Therapeutics.

Has Akari Therapeutics been receiving favorable news coverage?

News headlines about AKTX stock have trended somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akari Therapeutics earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Akari Therapeutics.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totalling 676,800 shares, an increase of 16.1% from the September 15th total of 583,000 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 334.9% of the shares of the company are sold short. View Akari Therapeutics' Current Options Chain.

Who are some of Akari Therapeutics' key competitors?

What other stocks do shareholders of Akari Therapeutics own?

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the folowing people:
  • Dr. Ray Prudo, Exec. Chairman (Age 74)
  • Mr. Clive Richardson, COO, Director & Interim CEO (Age 54)
  • Mr. Dov Elefant, Chief Financial Officer (Age 52)
  • Dr. Miles Nunn, Chief Scientific Officer

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Hikari Power Ltd (9.46%) and Virtu Financial LLC (0.20%). View Institutional Ownership Trends for Akari Therapeutics.

Which institutional investors are buying Akari Therapeutics stock?

AKTX stock was acquired by a variety of institutional investors in the last quarter, including Hikari Power Ltd and Virtu Financial LLC. View Insider Buying and Selling for Akari Therapeutics.

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.90.

How big of a company is Akari Therapeutics?

Akari Therapeutics has a market capitalization of $30.13 million. The biopharmaceutical company earns $-16,470,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Akari Therapeutics employs 17 workers across the globe.View Additional Information About Akari Therapeutics.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is http://www.akaritx.com/.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 646-350-0702 or via email at [email protected]


MarketBeat Community Rating for Akari Therapeutics (NASDAQ AKTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel